Galmed Pharmaceuticals (NASDAQ:GLMD) Announces Earnings Results, Beats Expectations By $0.26 EPS

Galmed Pharmaceuticals (NASDAQ:GLMD) announced its earnings results on Wednesday. The biopharmaceutical company reported ($2.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.12) by $0.26, FiscalAI reports.

Galmed Pharmaceuticals Price Performance

GLMD stock traded up $0.20 on Wednesday, hitting $4.12. 14,513 shares of the company were exchanged, compared to its average volume of 181,480. The stock has a market capitalization of $4.29 million, a price-to-earnings ratio of -0.57 and a beta of 0.74. Galmed Pharmaceuticals has a twelve month low of $3.29 and a twelve month high of $13.20. The business’s fifty day moving average is $4.43 and its two-hundred day moving average is $4.75.

Institutional Trading of Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned 1.28% of Galmed Pharmaceuticals at the end of the most recent reporting period. 76.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Galmed Pharmaceuticals presently has an average rating of “Sell”.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.